SML4083

TJ-M2010-5

Name: TJ-M2010-5
Brand: SIGMA

≥98% (HPLC)

别名:

3-(4-Benzyl-piperazin-1-yl)-N-(4-phenylthiazol-2-yl)propionamide, 3-(4-Benzylpiperazin-1-yl)-N-(4-phenylthiazol-2-yl)propanamide, 4-(Phenylmethyl)-N-(4-phenyl-2-thiazolyl)-1-piperazinepropanamide, TJ-5, TJM2010-5

登录查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:

C₂₃H₂₆N₄OS

化学文摘社编号:

1357471-57-8

分子量:

406.54

MDL number:

MFCD34578278

NACRES:

NA.21

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

主要文件

查看所有文档

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

SMILES string

O=C(CCN1CCN(CC1)CC2=CC=CC=C2)NC3=NC(C4=CC=CC=C4)=CS3

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Biochem/physiol Actions

TIR domain-targeting MyD88 homodimerization inhibitor that blocks MyD88 signaling and prevents colitis-associated cancer (CAC) development in vivo.

TJ-M2010-5 (TJ-5) is a TIR domain-targeting MyD88 homodimerization inhibitor (67% inhibition of HEK293 cellular MyD88 interaction at 20 µM) that blocks IRAK4, ERK and p38 phosphorylation induction by LPS stimulation (100 ng/mL for 6h with or without 40 µM TJ-5) in RAW 264.7 cells. TJ-5 (50 mg/kg/d i.p.) significantly reduces AOM/DSS-induced colitis and completely prevents colitis-associated cancer (CAC) development and death (53% mortality of control mice) in mice in vivo.